Effects on Plasma Lipids during Long Term Antihypertensive Treatment with Felodipine

Nielsen, M. R.; Winkel, O.; Ahlström, Fredrik; Frimodt-Møller, Jakob; Bøgeskov-Jensen, I.; Wickers-Nielsen, N.; Lassen, Erik

doi:10.1007/bf03258412

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a double-blind, placebo-controlled investigation over 12 weeks, Nilsson-Ehle found no significant effect of felodipine on plasma concentrations of triglycerides, total cholesterol, or LDL or HDL cholesterol (86). Similarly, during a 1-year open study with felodipine, Nielsen et al found no significant influence on triglycerides, total cholesterol, or LDL cholesterol (84). However, there was a slight, but significant, increase in HDL cholesterol and a decrease in the LDL/HDL ratio.…”

Section: Hormonal Metabolic and Laboratory Variablesmentioning

confidence: 95%

Tolerability and Safety of Felodipine

Elvelin

Kennerfalk

Elmfeldt

1993

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

Felodipine (Plendil@/Flodil@/Modip@, Astra) is a highly vascular selective calcium antagonist of the dihydropyridine type. At present, some 300 clinical studies involving more than 8,000 patients have been carried out with felodipine, the majority with hypertension but a substantial number also with other indications, such as angina pectoris and heart failure.In the early clinical studies, felodipine was given as conventional tablets twice daily. However, since 1986, most studies with felodipine have been performed using the extended-release formulation of the drug, which provides smoother plasma concentrations and 24-h blood pressure control with a once-daily dosage (11,37,38). This is the only formulation currently on the market.In controlled clinical trials, felodipine extended release once daily was found to be an effective antihypertensive treatment and reduced the blood pressure to S 9 0 mm Hg, 24 h after the dose, in 50430% of patients (13,22,41,65,82,106). Treatment with felodipine was reported to be more effective than with nifedipine, enalapril, chlorthalidone, or hydrochlorothiazide, but similarly effective to amlodipine, diltiazem, metoprolol, or aten-0101, at the doses studied (22,41,45,65,67,72,82,106,111). The aim of this article is to provide an overview of the experience with felodipine with regard to tolerability profile, effect on quality of life, safety in patients with diseases commonly occurring together with hypertension, effect on hormonal, metabolic, and laboratory variables, and interactions with food and drugs. PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIESFelodipine is a highly vascular selective dihydropyridine calcium antagonist. It has been shown to be over 100 times more potent in vascular than in cardiac muscle with a selectivity ratio nearly 10 times higher than that for the dihydropyridines nifedipine and amlodipine (73,87). In clinical studies, felodipine has been found to produce significant

show abstract

Section: Hormonal Metabolic and Laboratory Variablesmentioning

confidence: 95%

Tolerability and Safety of Felodipine

Elvelin

Kennerfalk

Elmfeldt

1993

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

show abstract

Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension

Notarbartoló¹,

Rengo²,

Scafidi³

et al. 1999

Current Therapeutic Research

View full text Add to dashboard Cite

Metabolic outcome during 1 year in newly detected hypertensives

Lindholm

Persson

Alaupovic

et al. 2003

Journal of Hypertension

274

View full text Add to dashboard Cite

Antihypertensive treatment with a diuretic, if needed combined with a beta-adrenoceptor blocker, was associated with an aggravated metabolic profile; this was not so for patients treated with an angiotensin-II-receptor blocker, if needed combined with a calcium antagonist. An antihypertensive treatment strategy that costs more in the short run but has no metabolic adverse effects may have a health economic impact in the long term.

show abstract

Effects on Plasma Lipids during Long Term Antihypertensive Treatment with Felodipine

Cited by 4 publications

References 8 publications

Tolerability and Safety of Felodipine

Tolerability and Safety of Felodipine

Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension

Metabolic outcome during 1 year in newly detected hypertensives

Contact Info

Product

Resources

About